Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02. Februar 2023 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
23. November 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
09. November 2022 07:30 ET
|
Xilio Therapeutics, Inc.
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with...
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
04. November 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
22. September 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
15. September 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
06. September 2022 16:05 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
09. August 2022 07:30 ET
|
Xilio Therapeutics, Inc.
XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial ...
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
16. Juni 2022 07:30 ET
|
Xilio Therapeutics, Inc.
Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO),...
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
18. Mai 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...